• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by DENTSPLY SIRONA Inc.

    6/5/25 5:25:28 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care
    Get the next $XRAY alert in real time by email
    FWP 1 d938745dfwp.htm FWP FWP

    Filed pursuant to Rule 433

    Free Writing Prospectus dated June 5, 2025

    Registration Statement No.: 333-286281

    DENTSPLY SIRONA Inc.

    Pricing Term Sheet—June 5, 2025

    $550,000,000 8.375% Junior Subordinated Notes due 2055

     

    Issuer:    DENTSPLY SIRONA Inc. (the “Issuer”)
    Description of Securities:    $550,000,000 8.375% Junior Subordinated Notes due 2055 (the “Notes”)
    Maturity Date:    September 12, 2055
    Settlement Date*:    June 12, 2025 (T+5)
    Issue Price:    100.000% of principal amount
    Interest Payment Dates:   

    Subject to our right to defer the payment of interest on the Notes as described under “Option to Defer Interest Payments” in the preliminary prospectus supplement, we will pay interest on the Notes semi-annually in arrears on March 12 and September 12 of each year, beginning on September 12, 2025.

    Interest on the Notes offered hereby will accrue from June 12, 2025.

    First Reset Date:    First Reset Date: September 12, 2030
    Reset Date:    First Reset Date and September 12 of every fifth year after 2030
    Interest Rate:    The Notes will bear interest (i) from, and including, the original issuance date to, but excluding, September 12, 2030 (“First Reset Date”) at a rate of 8.375% per year and (ii) from, and including, the First Reset Date, during each Reset Period, at a rate per year equal to the Five-year U.S. Treasury Rate as of the most recent Reset Interest Determination Date plus a spread of 4.379%, to be reset on each Reset Date; provided that the interest rate during any Reset Period will not reset below 8.375% (which equals the initial interest rate on the Notes).
    Optional Deferral of Interest:    Up to 10 consecutive years per deferral
    Tax Event Call:    The Notes are redeemable, in whole, but not in part, at 100% of the principal amount of the Notes, plus accrued and unpaid interest to, but excluding, the redemption date, by a date no later than 120 days following the occurrence of a Tax Event.
    Rating Agency Event Call:    The Notes are redeemable in whole but not in part, at 102% of the principal amount of the Notes, plus accrued and unpaid interest to, but excluding, the redemption date, by a date no later than 120 days following a Rating Agency Event.
    Optional Redemption Provisions:    We may redeem the Notes in whole or in part on one or more occasions at a price equal to 100% of the principal amount being redeemed, plus accrued and unpaid interest to, but excluding, the redemption date (i) on any day during the period commencing on the date that is 90 days prior to the First Reset Date and ending on and including the First Reset Date and (ii) after the First Reset Date, on any interest payment date for the Notes.


    Sole Book-Running Manager:   

    GOLDMAN SACHS & CO. LLC

    Co-Managers:   

    PNC CAPITAL MARKETS LLC

    COMMERZ MARKETS LLC

    TRUIST SECURITIES, INC.

    MUFG SECURITIES AMERICAS INC.

    CUSIP Number:   

    24906PAB5 / US24906PAB58

    Security Ratings**:   

    Baa3 (Moody’s) / BB (S&P)

     

    *

    It is expected that delivery of the Notes will be made against payment therefor on or about June 12, 2025, which is the fifth business day following the date hereof (such settlement cycle being referred to as “T+5”). Under Rule 15c6-1 under the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the Notes prior to the business day before the delivery of the notes under the prospectus supplement will be required, by virtue of the fact that the Notes initially will settle in T+5, to specify an alternative settlement cycle at the time of any such trade to prevent failed settlement. Purchasers of the Notes who wish to trade the Notes should consult their own advisors.

    **

    Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.

    The Company has filed a registration statement (including a prospectus and a prospectus supplement) with the Securities and Exchange Commission (“SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus and the prospectus supplement and other documents the Company has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the Company, any underwriter or any dealer participating in the offering will arrange to send you the prospectus and the prospectus supplement if you request it by calling Goldman Sachs & Co. LLC toll free at 1-866-471-2526.

    Any disclaimers or other notices that may appear below are not applicable to this communication and should be disregarded. Such disclaimers or other notices were automatically generated as a result of this communication being sent via Bloomberg or another email system.

    Get the next $XRAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XRAY

    DatePrice TargetRatingAnalyst
    4/15/2025$14.00Overweight → Equal-Weight
    Morgan Stanley
    3/13/2025Buy → Hold
    Needham
    2/14/2025$20.00Equal Weight
    Wells Fargo
    1/23/2025$30.00 → $20.00Buy → Hold
    Jefferies
    1/7/2025$20.00Outperform → In-line
    Evercore ISI
    12/4/2024$21.00Neutral
    Mizuho
    11/7/2024Outperform → Market Perform
    Leerink Partners
    10/25/2024$34.00 → $29.00Buy
    Needham
    More analyst ratings

    $XRAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dentsply Sirona Prices Offering of $550 million of Junior Subordinated Notes

      CHARLOTTE, N.C., June 05, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced it has priced an offering (the "Offering") of $550 million aggregate principal amount of its 8.375% Junior Subordinated Notes due 2055 (the "notes"). The Offering is expected to close on June 12, 2025, subject to customary closing conditions. The notes will bear interest at a fixed rate of 8.375% per year until September 12, 2030 (the "First Reset Date"). On and after the First Reset Date, the interest rate per year on the notes for each reset period will be equal to the five-year U.S. Treasury rate as of the most recent reset interest rate determinati

      6/5/25 5:35:00 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona Appoints Matthew E. Garth as Chief Financial Officer

      CHARLOTTE, N.C., May 29, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Matthew E. Garth has been appointed Executive Vice President and Chief Financial Officer, effective May 30, 2025. Mr. Garth brings nearly 30 years of proven financial management expertise to Dentsply Sirona, with a focus on driving value creation. He most recently served as Chief Financial Officer & Chief Administrative Officer of The Scotts Miracle-Gro Company, a global leader of branded consumer lawn and garden products. Prior to ScottsMiracle-Gro, Mr. Garth held numerous financial leadership roles at large, multinational companies, including Min

      5/29/25 4:30:00 PM ET
      $MTX
      $SMG
      $XRAY
      Major Chemicals
      Industrials
      Agricultural Chemicals
      Medical/Dental Instruments
    • Dentsply Sirona Declares Quarterly Cash Dividend

      CHARLOTTE, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on July 11, 2025, to holders of record as of June 27, 2025. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and

      5/27/25 4:15:00 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dentsply Sirona downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Dentsply Sirona from Overweight to Equal-Weight and set a new price target of $14.00

      4/15/25 9:24:19 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona downgraded by Needham

      Needham downgraded Dentsply Sirona from Buy to Hold

      3/13/25 7:58:34 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Wells Fargo initiated coverage on Dentsply Sirona with a new price target

      Wells Fargo initiated coverage of Dentsply Sirona with a rating of Equal Weight and set a new price target of $20.00

      2/14/25 7:09:40 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Leadership Updates

    Live Leadership Updates

    See more
    • Dentsply Sirona Appoints Matthew E. Garth as Chief Financial Officer

      CHARLOTTE, N.C., May 29, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Matthew E. Garth has been appointed Executive Vice President and Chief Financial Officer, effective May 30, 2025. Mr. Garth brings nearly 30 years of proven financial management expertise to Dentsply Sirona, with a focus on driving value creation. He most recently served as Chief Financial Officer & Chief Administrative Officer of The Scotts Miracle-Gro Company, a global leader of branded consumer lawn and garden products. Prior to ScottsMiracle-Gro, Mr. Garth held numerous financial leadership roles at large, multinational companies, including Min

      5/29/25 4:30:00 PM ET
      $MTX
      $SMG
      $XRAY
      Major Chemicals
      Industrials
      Agricultural Chemicals
      Medical/Dental Instruments
    • Dentsply Sirona Appoints David Ferguson as Global Business Unit Leader

      CHARLOTTE, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (XRAY) today announced that David Ferguson has been appointed Senior Vice President, Global Business Unit Leader, effective March 14, 2025. In this role he will lead the global business unit teams managing the dental product portfolio, serve as a member of the Executive Management Team and report directly to Chief Executive Officer, Simon Campion. David Ferguson joins Dentsply Sirona with 25 years of experience in MedTech and healthcare with a proven track record of delivering results, competing in a global marketplace and leading global product strategy. Mr. Ferguson has se

      3/17/25 8:45:57 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

      CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

      2/6/25 8:30:00 AM ET
      $EXAS
      $GE
      $GMED
      $XRAY
      Medical Specialities
      Health Care
      Consumer Electronics/Appliances
      Technology

    $XRAY
    Financials

    Live finance-specific insights

    See more
    • Dentsply Sirona Declares Quarterly Cash Dividend

      CHARLOTTE, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on July 11, 2025, to holders of record as of June 27, 2025. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and

      5/27/25 4:15:00 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona Reports First Quarter 2025 Results

      Net sales of $879 million decreased (7.7%), organic sales decreased (4.4%) including a (4.0%) Byte sales impactGAAP gross margin of 53.0%, GAAP net income of $20 million or $0.10 per shareAdjusted gross margin of 56.3%, adjusted EBITDA margin of 19.0%, adjusted EPS of $0.43Maintaining FY25 outlook for organic sales and adjusted EPS; increasing reported sales due to F/X changes CHARLOTTE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its financial results for the first quarter of 2025. First quarter net sales of $879 million decreased (7.7%) (organic sales decreased (4.4%)) compared to the first quarter of 2

      5/8/25 6:00:00 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona to Host First Quarter Conference Call on May 8th

      CHARLOTTE, N.C., April 09, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, May 8, 2025, at 8:30 am ET to review its first quarter financial results. A presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. Conference Call / Webcast Information A live webcast will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register at https://register-conf

      4/9/25 7:00:00 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    SEC Filings

    See more
    • SEC Form 8-K filed by DENTSPLY SIRONA Inc.

      8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

      6/6/25 8:21:14 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form FWP filed by DENTSPLY SIRONA Inc.

      FWP - DENTSPLY SIRONA Inc. (0000818479) (Subject)

      6/5/25 5:25:28 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by DENTSPLY SIRONA Inc.

      8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

      6/4/25 6:37:35 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lucier Gregory T bought $249,994 worth of shares (15,142 units at $16.51), increasing direct ownership by 23% to 81,971 units (SEC Form 4)

      4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      3/3/25 6:33:03 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Amendment: Director Lucier Gregory T bought $110,129 worth of shares (6,000 units at $18.35), increasing direct ownership by 8% to 66,730 units (SEC Form 4)

      4/A - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      1/29/25 6:14:01 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Director Lucier Gregory T bought $110,129 worth of shares (6,000 units at $18.35), increasing direct ownership by 7% to 71,730 units (SEC Form 4)

      4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      11/18/24 4:16:34 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by DENTSPLY SIRONA Inc.

      SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)

      12/6/24 10:11:29 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

      SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

      11/14/24 1:22:35 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

      SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

      11/12/24 4:23:31 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & CFO Garth Matthew E was granted 43,023 shares (SEC Form 4)

      4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      6/3/25 4:48:31 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Garth Matthew E

      3 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      5/30/25 4:27:32 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Director Vergis Janet S. was granted 13,880 shares, increasing direct ownership by 46% to 43,981 units (SEC Form 4)

      4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      5/27/25 5:26:57 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care